At present, the first-line treatment drug temozolomide (TMZ) can effectively improve glioma and astrocytoma with low expression of DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT), while the clinical treatment for glioma with high MGMT expression is still lacking [4]. The gene discussed is MGMT; the disease is central nervous system cancer.